CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0392 (clinicaltrials.gov NCT No: NCT01576666)
Title:A Phase Ib, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors
Principal Investigator:Marta Penas-Prado
Treatment Agent:BKM120; LDE225
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of LDE225 that can be given in combination with BKM120 in patients with
glioblastoma. The safety of the drug combination will also be studied.

LDE225 and BKM120 are designed to block certain proteins that are important to
the growth and division of cancer cells, which may cause the cells to die.

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase I
Treatment Agents:BKM120
LDE225
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marta Penas-Prado
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults